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Abstract 
Background: Glioblastoma (GBM) is a highly aggressive primary brain cancer, for which curative therapies are not 
available. An emerging therapeutic approach suggested to have potential to target malignant gliomas has been 
based on the use of multipotent mesenchymal stem cells (MSCs), either unmodified or engineered to deliver antican-
cer therapeutic agents, as these cells present an intrinsic capacity to migrate towards malignant tumors. Nevertheless, 
it is still controversial whether this innate tropism of MSCs towards the tumor area is associated with cancer promo-
tion or suppression. Considering that one of the major mechanisms by which MSCs interact with and modulate 
tumor cells is via secreted factors, we studied how the secretome of MSCs modulates critical hallmark features of GBM 
cells.
Methods: The effect of conditioned media (CM) from human umbilical cord perivascular cells (HUCPVCs, a MSC 
population present in the Wharton’s jelly of the umbilical cord) on GBM cell viability, migration, proliferation and 
sensitivity to temozolomide treatment of U251 and SNB-19 GBM cells was evaluated. The in vivo chicken chorioallan-
toic membrane (CAM) assay was used to evaluate the effect of HUCPVCs CM on tumor growth and angiogenesis. The 
secretome of HUCPVCs was characterized by proteomic analyses.
Results: We found that both tested GBM cell lines exposed to HUCPVCs CM presented significantly higher cellular 
viability, proliferation and migration. In contrast, resistance of GBM cells to temozolomide chemotherapy was not 
significantly affected by HUCPVCs CM. In the in vivo CAM assay, CM from HUCPVCs promoted U251 and SNB-19 
tumor cells growth. Proteomic analysis to characterize the secretome of HUCPVCs identified several proteins involved 
in promotion of cell survival, proliferation and migration, revealing novel putative molecular mediators for the effects 
observed in GBM cells exposed to HUCPVCs CM.
Conclusions: These findings provide novel insights to better understand the interplay between GBM cells and MSCs, 
raising awareness to potential safety issues regarding the use of MSCs as stem-cell based therapies for GBM.
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Secretome, Viability, Proliferation, Migration, Proteomics
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Gliomas are the most common primary malignancies 
in the central nervous system (CNS), accounting for 
approximately 80% of all primary brain tumors [1]. Glio-
blastoma (GBM, grade IV) is the most common and 
malignant type of glioma in adults, presenting a high 
mortality rate and very poor patient outcomes. In fact, 
despite multimodal therapeutic approaches consist-
ing of surgery, chemotherapy and radiotherapy, virtually 
all GBMs recur and lead to death, presenting a median 
overall survival of  ~  15  months [2]. This poor outcome 
has not changed significantly in the last decades, stress-
ing the need for novel therapeutic strategies that may, 
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more efficiently, overcome the highly resistance nature 
of these tumors. A novel therapeutic approach currently 
being investigated for a variety of cancer types is based 
on the use of tumor-trophic stem cells, such as mesen-
chymal stem cells (MSCs) [3–17]. These are multipotent 
progenitor cells that are defined according to 3 main 
characteristics: (i) expression of CD105, CD73 and CD90 
(MSCs markers), and lack of expression of CD45, CD34, 
CD14 (hematopoietic markers); (ii) ability to adhere to 
plastic surfaces; and (iii) differentiation capacity into adi-
pocytes, osteoblasts and chondrocytes (multipotency) 
[18, 19]. Additionally, MSCs are also characterized by 
their proliferative and self-renewal abilities, and can be 
isolated from bone marrow (BM-MSCs) [20], adipose 
tissue (ASCs) [21], umbilical cord (e.g., human umbili-
cal cord perivascular cells; HUCPVCs) [22–24], among 
other sources [25–30]. The use of MSCs is relatively 
promising since these cells: (i) can be easily isolated and 
subsequently expanded in  vitro; (ii) show multi-lineage 
differentiation ability; (iii) have an immune privileged 
nature; (iv) present capacity to home for site of injury, 
including tumors; and (v) are amenable to genetic modi-
fication [31, 32]. In fact, it was already demonstrated that 
MSCs present an intrinsic capacity to migrate towards 
gliomas and present low immunogenicity at autologous 
transplantation [3, 10–12, 33–42]. However, whether this 
selective MSC tumor-tropism is associated with cancer 
suppression or promotion functions is still controversial 
[3, 10, 11, 13, 34, 35, 43]. Several studies, using MSCs 
engineered to express anti-glioma agents, demonstrated 
that these cells are highly effective as anti-tumor deliv-
ery agents [10, 11, 36, 38, 42, 44, 45]. However, few stud-
ies have evaluated the impact of non-engineered MSCs 
on glioma behavior [3, 12, 13, 46], so it is still unclear if 
MSCs either promote or repress tumor features. Akimoto 
and colleagues showed that umbilical cord blood-derived 
MSCs induced apoptosis in glioma cells; however, in 
the same study, adipose-derived MSCs enhanced the 
growth of GBM cells [3]. In another study, co-culturing 
of adipose-derived MSCs with human glioma cells led 
to higher survival and proliferation of glioma cells [12], 
whereas in another study, bone marrow-derived MSCs 
co-cultured with human glioma cells inhibited tumor cell 
proliferation [46]. Therefore, further studies focusing on 
the crosstalk between tumor cells and MSCs should be 
performed to strengthen the evidence that MSCs-based 
therapies could be efficiently and safely translated into 
clinical settings.
This study evaluates how the secretome of a population 
of MSCs isolated from Wharton Jelly of the umbilical 
cord (HUCPVCs) modulates critical hallmark features of 
GBM. In particular, using in vitro and in vivo models, we 
investigated the effect of HUCPVCs conditioned media 
(CM) on GBM cells viability, growth, migration, prolif-
eration, angiogenesis, and response to chemotherapy. 
Proteomic analysis of HUCPVCs CM was performed to 
identify molecular players that can influence the behav-
ior of GBM cells, which may identify novel targets for 
therapy.
Methods
Cell lines
The human glioblastoma cell line SNB-19 was kindly pro-
vided by Rui M. Reis, (Life and Health Sciences Research 
Institute (ICVS), School of Medicine, University of 
Minho, Portugal) and the human glioblastoma cell line 
U251 was kindly provided by Professor Joseph Costello, 
(Department of Neurological Surgery, University of Cali-
fornia, San Francisco (UCSF), USA). Both cell lines were 
cultured as monolayers in Dulbecco’s Modified Eagle 
Medium (DMEM; Biochrom) supplemented with 10% 
(v/v) inactivated fetal bovine serum (FBS; Biochrom), and 
1% (v/v) penicillin/streptomycin (Invitrogen). The human 
umbilical cord perivascular cells (HUCPVCs) were kindly 
provided by Prof. John E. Davies (University of Toronto, 
Toronto, Canada), and were previously characterized at 
the immunophenotype and functional levels [47, 48], and 
were grown as monolayers in alpha-Minimum Essential 
Medium (α-MEM;  Gibco®) supplemented with 10% FBS 
(Biochrom) and 1% penicillin/streptomycin (Invitrogen). 
All cell lines were incubated at 37  °C in a humidified 
atmosphere with 5% (v/v)  CO2.
HUCPVCs conditioned media (CM) collection
CM were collected from HUCPVCs in culture at passage 
6 (P6). HUCPVCs were plated (at a density of 4 ×  103 
cells/cm2 for in vitro functional assays, or 12 × 103 cells/
cm2 for proteomic assay) and allowed to grow for 72 h. 
Subsequently, cells were washed (2 × for in vitro assays, 
or 5x for proteomic assay) with phosphate buffer solu-
tion (PBS) and the medium was replaced by DMEM 
with 1% penicillin/streptomycin. CM were collected 
after 48 h (culture media was not renewed or added dur-
ing this period), filtrated through 0.22 µm filters, imme-
diately snap-frozen and stored at −  80  °C. A total of 7 
independent CMs were collected (N  =  7), and at least 
2 independent CMs were used per each in  vitro func-
tional assay, each of which was repeated at least 3 times. 
For proteomic analysis, 1 CM was used. Before use, CMs 
were thawed overnight at 4 °C. For the in vitro functional 
assays, 1% of FBS was added to the media (HUCPVCs 
CM) as GBM cells are not able to grow without FBS; the 
control condition consisted of DMEM containing 1% FBS 
and 1% penicillin/streptomycin (control media). For pro-
teomic analysis, control media consisted of DMEM con-
taining 1% penicillin/streptomycin.
Page 3 of 14Vieira de Castro et al. J Transl Med  (2017) 15:200 
Cell viability assessment
Trypan blue
U251 and SNB-19 GBM cells were plated in triplicates, at 
an initial density of 5 × 104 and 1 × 105 cells per well in 
24-well plates, respectively. After 24 h, HUCPVCs CM or 
control media were added to cells and incubated for 2, 4, 
and 6 days (CM and control media were renewed every 
48 h). At each time point, total cells were trypsinized and 
the suspension mixed with trypan blue (1:1 ratio). The 
number of viable cells were counted in duplicates using 
hemocytometers. Results represent the mean ± standard 
deviations (SD) of at least 3 independent experiments.
MTT assay
U251 and SNB-19 GBM cells were plated in triplicates, at 
an initial density of 2.5 × 104 and 5 × 104 cells per well in 
48-well plates, respectively. After 24 h, HUCPVCs CM or 
control media were added to cells and incubated for 2, 4, 
and 6 days (CM and control media were renewed every 
48 h). At each time point, a MTT solution (Thermo Sci-
entific; 0.5  mg of MTT per 1  mL of PBS) was added to 
each well, followed by incubation in a humidified atmos-
phere, at 37 °C and 5% (v/v)  CO2, for 1 h. The optical den-
sity was measured at 570 nm using a microplate reader. 
Results are presented as the mean ± SD of at least 3 inde-
pendent experiments.
Response to temozolomide chemotherapy
To evaluate the effect of HUCPVCs CM on the response 
of GBM cells to temozolomide (TMZ, Sigma-Aldrich, 
dissolved in DMSO), the half-maximal inhibitory con-
centration  (IC50) of TMZ on U251 and SNB-19 GBM 
cells was determined by MTT assay. U251 and SNB-19 
GBM cells were plated in triplicates, at an initial density 
of 1 ×  104 and 2 ×  104 cells per well in 24-well plates, 
respectively. After 24 h, cells were washed once with PBS 
and treated with different doses of TMZ (5, 10, 20, 35, 
50, 100, 500 μM; or 25, 50, 100, 175, 250, 500, 1000 μM; 
for U251 and SNB-19 cells, respectively) or vehicle (1% 
DMSO) in HUCPVCs CM or control media for 5  days 
(medium with drugs or vehicle was renewed after 2 days). 
Results are presented as the mean ± SD of 3 independent 
experiments.
Migration (wound healing) assay
U251 and SNB-19 GBM cells were plated in triplicates, 
at an initial density of 5 ×  105 and 2.5 ×  105 cells/well 
in 12-well plates, respectively. After 24 h, a confluent cell 
monolayer was formed, and a wound was made by manu-
ally scratching with a 200 µL pipette tip. Cells in suspen-
sion were removed, and adherent cells were washed once 
with PBS. HUCPVCs CM or control media were carefully 
added to cells. At this point (0  h), the “wounded” areas 
were photographed at 4 distinct places, at 40 × magni-
fication by phase contrast microscopy. The same areas 
were subsequently photographed to monitor wound 
closure after 16, 24 and 48  h. Migration distances were 
measured using the be Wound—Cell Migration Tool 
(Version 1.5) as previously described [49]. Relative wound 
closure was calculated for each time point. Results are 
presented as percentages of wound closure and represent 
the mean ± SD of at least 3 independent experiments.
Cell proliferation assay
To evaluate the impact of HUCPVCs CM on GBM cells 
proliferation, the Cell Proliferation ELISA, 5-bromo-
2´-deoxyuridine assay (BrdU, Cell Proliferation ELISA, 
Applied Sciences) was used as indicated by the manu-
facturer. Briefly, U251 and SNB-19 GBM cells were 
plated in triplicates, at an initial density of 1.5 × 103 and 
2.5  ×  103 cells per well, in 96-well plates, respectively, 
and grown overnight. Then, adherent cells were treated 
with HUCPVCs CM or control media for 3  days. After 
this period, cells were labeled with 10 μL/well of 100 μM 
BrdU labeling solution, and reincubated for 16  h. BrdU 
incorporation was assessed according to the manufac-
turer’s protocol. In order to ensure that the absorbance 
obtained was a result of proliferating cells, and not simply 
from a higher number of viable cells, a 96-well plate con-
taining U251 and SNB-19 cells plated and treated in the 
same conditions as described for BrdU assay, was done 
to perform MTT assay, following the method described 
above. Results are presented as the ratio between BrdU 
positive cells and MTT positive (viable) cells and repre-
sent the mean ± SD of 3 independent experiments.
Chicken chorioallantoic membrane (CAM) assay
CAM assay was performed as previously described [50]. 
Briefly, fertilized chicken eggs (supplied by Pinto Bar, 
Portugal) were incubated at 37 °C in a humidified atmos-
phere, and on day 3 of development, a window was made 
into the eggshell after puncturing the air chamber, and 
eggs were sealed with BTK tape and returned to the 
incubator. On day 9 of development, 2  ×  106 U251  or 
SNB-19 cells, previously exposed to HUCPVCs CM or 
control media during 4 days, were re-suspended on 10 µL 
of Matrigel (BD Biosciences), placed on the CAM, and 
the eggs were tapped and returned to the incubator. At 
days 11, 13 and 15 of incubation, 100 µL of new CM or 
control media was added to each respective group. On 
developmental day 17, tumors were photographed in ovo 
using a stereomicroscope (Olympus S2x16). The chicken 
embryos were sacrificed at −  80  °C for 10  min. CAMs 
and tumors were dissected, fixed in 4% paraformalde-
hyde at room temperature, and photographed ex ovo. The 
area of the tumors was measured using Cell B software 
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(Olympus), and blood vessels from a selected area con-
taining the tumor were quantified using the Image J soft-
ware. A total of 38 (U251) and 42 (SNB-19) fertilized 
chicken eggs were used, 14 (U251) and 15 (SNB-19) in 
the control group, and 24 (U251) and 27 (SNB-19) in the 
HUCPVCs CM group.
RNA extraction, cDNA synthesis and qRT‑PCR
Total RNA from HUCPVCs (N  =  3) cultured in the 
same conditions as for CM collection (P6) was extracted 
with Trizol (Invitrogen) according to the manufacturer’s 
instructions. cDNA synthesis was performed using 1 µg 
of total RNA with High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). Gene-specific mRNA 
levels were assessed by quantitative real-time PCR 
(qPCR) in a real-time thermocycler (CFX96; Bio-Rad) 
using Fast SYBR Green (Qiagen) according to the manu-
facturer’s instructions, by the  2−ΔΔCt method. The list of 
primers used can be found in Additional file 1: Table S1.
Proteomics analysis
Sample preparation
HUCPVCs CM and control media spiked with the same 
amount of the recombinant protein malE-GFP (to be 
use as internal standard) were firstly concentrated using 
a Vivaspin 20 sample concentrator (5  kDa; GE Health-
care) by centrifugation at 3000 g. Concentrated CM and 
control media were precipitated with Trichloroacetic 
acid (TCA)-Acetone [51]. The washed pellets were res-
suspended in 2  ×  Laemmli buffer (BioRad)), aided by 
ultrasonication and denaturated at 95  °C [52]. After 
denaturation, samples were alkylated with acrylamide 
and subjected in gel digestion by using the short-GeLC 
approach [53]. The entire lanes were sliced into 3 parts, 
and each part was sliced in small pieces and processed. 
Gel pieces were destained, dehydrated and re-hydrated in 
75 µL of trypsin (0.01 µg/µL solution in 10 mM ammo-
nium bicarbonate) for 15 min, on ice. Thirty µL of 10 mM 
ammonium bicarbonate were then added and in-gel 
digestion was performed overnight, at room tempera-
ture. After digestion, the formed peptides were extracted 
from the gel pieces by sequential addition of three solu-
tions of acetonitrile (ACN) in 1% formic acid (FA) (30, 
50, and 98% of ACN, respectively). All the peptides were 
dried and subjected to SPE using OMIX tips with C18 
stationary phase (Agilent Technologies) as recommended 
by the manufacture. Eluates were dried and ressuspended 
with a solution of 2% ACN and 0.1% FA.
SWATH‑MS acquisition
Samples were analyzed on a Triple TOF™ 5600 System 
 (ABSciex®) in two different phases: information-dependent 
acquisition (IDA) and SWATH acquisition. Peptides were 
resolved by liquid chromatography (nanoLC Ultra 2D, 
 Eksigent®) on a MicroLC column ChromXP™ C18CL 
(300  μm ID ×  15  cm length, 3  μm particles, 120 Å pore 
size,  Eksigent®) at 5  μL/minutes with a multistep gradi-
ent: 0–2  min linear gradient from 5 to 10%, 2–45  min 
linear gradient from 10 to 30% and, 45–46  min to 35% 
of ACN in 0.1% FA. Peptides were eluted into the mass 
spectrometer using an electrospray ionization source 
(DuoSpray™  Source,  ABSciex®) with a 50  μm internal 
diameter (ID) stainless steel emitter (NewObjective). IDA 
experiments were performed for each 3 peptide mixtures 
per samples. The mass spectrometer was set to scanning 
full spectra (350–1250 m/z) for 250 ms, followed by up to 
100 MS/MS scans (100–1500  m/z from a dynamic accu-
mulation time—minimum 30  ms for precursor above the 
intensity threshold of 1000—with the purpose of maintain-
ing a cycle time of 3.3 s). Candidate ions with a charge state 
between + 2 and + 5 and counts above a minimum thresh-
old of 10 counts per second were isolated for fragmentation 
and one MS/MS spectra was collected before adding those 
ions to the exclusion list for 25 s (mass spectrometer oper-
ated by  Analyst® TF 1.7,  ABSciex®). Rolling collision was 
utilized with a collision energy spread of 5.
The 3 peptide mixtures of each sample were com-
bined and concentrated, and a single analysis of each 
sample was set for quantitative analysis by acquisition 
in SWATH mode. For SWATH-MS based experiments, 
the mass spectrometer was operated in a looped prod-
uct ion mode [54] and the same chromatographic con-
ditions used as in the IDA run described above. The 
SWATH-MS setup was specifically designed for the 
samples to be analyzed (Additional file 2: Table S2), in 
order to adapt the SWATH windows to the complexity 
of the set of samples. A set of 60 windows of variable 
width (containing 1  m/z for the window overlap) was 
conceived covering the precursor mass range of 350–
1250  m/z. A 250  ms survey scan (350–1500  m/z) was 
acquired at the beginning of each cycle and SWATH 
MS/MS spectra were collected from 100-1500  m/z for 
50 ms resulting in a cycle time of 3.25 s from the precur-
sors ranging from 350 to 1250 m/z. The collision energy 
for each window was determined according to the cal-
culation for a charge +2 ion centered upon the window 
with variable collision energy spread (CES) according 
with the window.
A specific library of precursor masses and fragment 
ions was created by combining all files from the IDA 
experiments, and used for subsequent SWATH process-
ing. Peptide identification and library generation were 
performed with Protein Pilot software (v5.1,  ABSciex®), 
using the following parameters: (i) search against a 
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database composed by Homo Sapiens from SwissProt 
(release at April 2016), and malE-GFP; (ii) acrylamide 
alkylated cysteines as fixed modification; and (iii) trypsin 
as digestion type. An independent false discovery rate 
(FDR) analysis using the target-decoy approach provided 
with Protein Pilot software was used to assess the qual-
ity of the identifications and positive identifications were 
considered when identified proteins and peptides reached 
a 5% local FDR [55, 56]. Data processing was performed 
using SWATH™ processing plug-in for PeakView™ 
(v2.0.01,  ABSciex®) as described in [53]. After retention 
time adjustment using the malE-GFP peptides, up to 15 
peptides, with up to 5 fragments each, were chosen per 
protein, and quantitation was attempted for all proteins 
in the library file that were identified below 5% local 
FDR from ProteinPilot™ searches. Peptides’ confidence 
threshold was determined based on a FDR analysis using 
the target-decoy approach and the peptides that met the 
1% FDR threshold in HUCPVCs sample were retained, 
and the peak areas of the target fragment ions of those 
peptides were extracted across the experiments using an 
extracted-ion chromatogram (XIC) window of 4 min and 
a XIC width of 100  ppm. The levels of the human pro-
teins were estimated by summing all the filtered transi-
tions from all the filtered peptides for a given protein (an 
adaptation of [57]) normalized to the internal standard 
(malE-GFP).
Functional clustering analysis
The identified expressed proteins in HUCPVCs CM 
were analyzed using the DAVID (Database for Anno-
tation, Visualization and Integrated Discovery) bioin-
formatics resources version 6.7 (https://david.ncifcrf.
gov/) [58, 59]. The list of Uniprot Accession IDs was 
loaded into the online tool and mapped against refer-
ence Homo sapiens dataset to extract and summarize 
functional classification. In DAVID analyses the pro-
teins identified were displayed in Kyoto encyclopedia of 
genes and genomes (KEGG), Gene ontology (GO), or 
Reactome pathways.
Statistical analysis
All statistical analyses were performed using GraphPad 
Prism 6.0 (GraphPad software, Inc.). To assess the sta-
tistical differences between groups, unpaired Student’s t 
test analysis was performed.  IC50 values were calculated 
by a nonlinear regression (curve Fit) based on sigmoidal 
dose-response (variable slope), and two-way repeated-
measures analysis of variance (ANOVA) test was used to 
assess statistical differences between conditions. Results 
are presented as normalized mean ±  SD, and statistical 
significance was defined as p < 0.05 for a 95% confidence 
interval.
Results
HUCPVCs conditioned media (CM) enhance glioblastoma 
cell viability, migration and proliferation, and do not affect 
sensitivity to temozolomide chemotherapy
Taking into consideration the controversial reports on 
the roles of MSCs on tumor behavior, we started by eval-
uating how the secretome of HUCPVCs modulates criti-
cal hallmark features of GBM cells, particularly viability, 
proliferation and migration. Using two GBM cell lines, 
U251 and SNB-19, and CM from HUCPVCs, we evalu-
ated GBM cell viability using two complementary assays: 
MTT (Fig. 1a, b) and trypan blue (Fig. 1c, d). Both U251 
and SNB-19 cell lines presented a statistically significant 
increase in cell viability after exposure to HUCPVCs CM, 
in all tested time points (shown both by MTT and trypan 
blue assays; Fig. 1).
GBM cell migration was evaluated by a wound healing 
assay (Fig.  2) on U251 (Fig.  2a, b) and SNB-19 (Fig.  2c, 
d) cells exposed to HUCPVCs CM. We found that both 
GBM cell lines, when exposed to CM, presented a statis-
tically significant higher migration capacity when com-
pared to control/unexposed conditions (Fig. 2).
Subsequently, the effect of HUCPVCs CM on GBM 
cell proliferation was evaluated by the BrdU cell prolif-
eration assay (Fig. 3a, c). Both U251 (Fig. 3a) and SNB-19 
(Fig. 3c) GBM cells exposed to HUCPVCs CM showed a 
statistically significant increase in cell proliferation when 
compared with control conditions.
The influence of HUCPVCs CM exposure on the 
response of GBM cells to temozolomide (TMZ)-based 
chemotherapy was then evaluated (Fig.  3b, d). The half 
inhibitory concentration  (IC50) values after 5  days of 
TMZ treatment were determined for U251 (Fig. 3b) and 
SNB-19 (Fig. 3d) cells. In contrast to the notorious effects 
previously observed in cell viability, migration, and pro-
liferation, no significant differences were observed in 
the sensitivity of U251 and SNB-19 cells to TMZ when 
exposed to HUCPVCs CM versus their respective con-
trols (Fig. 3b, d).
HUCPVCs conditioned media (CM) increase in vivo tumor 
growth of GBM cells
In order to complement the in vitro studies, the effect of 
HUCPVCs CM on GBM 3D tumor growth and angio-
genesis was then evaluated using the in vivo Chick Chori-
oallantoic Membrane (CAM) assay, which allows efficient 
tumor formation and vascularization [50]. Concordantly 
with the in  vitro data, both U251 (Fig.  4a, c) and SNB-
19 (Fig.  4b, d) GBM cells exposed to HUCPVCs CM 
implanted in the CAM formed statistically significantly 
larger tumors than those derived from cells exposed to 
control media (p = 0.0260 and p = 0.0290, respectively). 
Regarding vessel density, CM-exposed U251 and SNB-19 
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GBM tumors presented a general increase in vessel den-
sities compared with control-exposed tumors (Fig. 4e–h), 
but only SNB-19-derived tumors reached statistical sig-
nificance (p = 0.0069; Fig. 4f, h).
HUCPVCs conditioned media (CM) contain key proteins 
involved in cell viability, migration, and proliferation, 
commonly dysregulated in GBM
Considering the broad consistent effects of HUCPVCs 
CM on the behavior of tumor cells both in  vitro and 
in vivo, we performed proteomic analyses of HUCPVCs 
CM to identify the protein content of their secretome 
that may putatively influence GBM behavior. A total of 
699 proteins were identified in our proteomic analysis 
(N = 1; Additional file 3: Table S3). Concordantly, quan-
titative RT-qPCR analyses detected mRNA expression 
of seven genes coding for proteins detected in the pro-
teomic analyses of HUCPVCs (CCL2, TPT1, POSTN, 
TGFβI, SEMA7A, PDGFC, and IL6; Additional file 4: Fig-
ure S1), fitting well with our proteomic data.
To better understand the biological functions of these 
secreted proteins, we employed functional cluster-
ing annotation using and integration into Gene Ontol-
ogy (GO), Kyoto encyclopedia of genes and genomes 
(KEGG) and Reactome analyses (Fig.  5). Biological pro-
cesses and cellular components related to extracellular 
matrix (ECM) organization were the most enriched in 
HUCPVCs CM (Fig.  5a, b), whereas actin binding was 
the most represented molecular function among all iden-
tified proteins (Fig.  5c). Proteins involved in cell cycle, 
adhesion, motion, survival, migration, and differentia-
tion, which are well known to be key regulators of a vari-
ety of physiological processes but also to be dysregulated 
in cancer cells, were amongst the most abundantly iden-
tified (Fig.  5a). The HUCPVCs secretome was enriched 
for several pathways by Reactome and KEGG analyses 
(Fig. 5d, e), including Wnt, platelet-derived growth factor 
(PDGF), vascular endothelial growth factor (VEGF) and 
pentose phosphate signaling pathways, as well as proteins 
involved in focal adhesion, ECM-receptor interaction 
Fig. 1 Effect of HUCPVCs conditioned media (CM) on GBM cell viability. Cell viability was measured by MTT (a, b) and trypan blue (c, d) assays on 
U251 (a, c) and SNB-19 (b, d) GBM cell lines, after exposure to control media or HUCPVCs CM. HUCPVCs CM led to a statistically significant increase 
in viability of GBM cells in both assays, in all tested time points. All experiments were done in triplicate, at least in 3 independent experiments. Data 
is presented as the mean ± SD (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001)
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Fig. 2 Effect of HUCPVCs conditioned media (CM) on GBM cell migration. a, c Representative pictures showing the migratory capacity of U251 (a) 
and SNB-19 (c) GBM cells exposed to control media or HUCPVCs CM. b, c Quantification of U251 (b) and SNB-19 (d) cell migration presented as % of 
wound closure. Treatment with HUCPVCs CM led to a statistically significant increase of GBM cell migration. Data is presented as the mean ± SD of 
at least 3 independent experiments, each in triplicate (*p ≤ 0.05 and **p ≤ 0.01)
Fig. 3 Effect of HUCPVCs conditioned media (CM) on GBM cell proliferation and sensitivity to temozolomide treatment. a, c Proliferation capacity 
of U251 (a) and SNB-19 (c) GBM cells was determined by BrdU assay after treatment with control media or HUCPVCs CM. Exposure to HUCPVCs CM 
increased the proliferation rate of both GBM cell lines (**p ≤ 0.01). b, d Determination of the half inhibitory concentration  (IC50) values of temozo-
lomide (TMZ) treatment in U251 (b) and SNB-19 (d) cell lines. For both cell lines, no statistically significant differences in the TMZ  IC50 values were 
found between cells treated with HUCPVCs CM or control media (p = 0.6738 for U251, and p = 0.3115 in SNB-19). Results are expressed as the 
mean ± SD of 3 independent experiments, each in triplicate
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and DNA replication. Globally, these data identify a set 
of biological processes and pathways that are well-known 
to be involved in the regulation of physiological pro-
cesses, but also to be altered in cancer, which may partly 
explain the effects of HUCPVCs CM observed in GBM 
cell behavior.
Discussion
One of the major concerns in stem cell-based therapies is 
the impact that modified stem cells may have on tumor 
behavior. MSCs have been proposed as a new therapeu-
tic approach for glioma treatment, because these cells 
have been found to have tumor chemotactic capabili-
ties and migrate towards tumor sites through the blood-
brain-barrier, where continuous bilateral molecular 
crosstalks occur between stromal and cancer cells [60, 
61]. Although some studies suggested that MSCs inhibit 
tumor growth, others demonstrated that MSCs have 
a pro-tumoral function by stimulating tumor growth, 
migration, invasion, and anticancer-drug resistance 
[3, 12, 13, 62]. The pro-tumoral effects are mediated by 
secreted molecules and/or via direct cellular interactions 
[10, 15, 33–35, 63–70]. Therefore, the clinical validity of 
MSCs as a potential therapeutic approach for glioma is 
still a matter of debate, deserving further clarification. 
In this study, we evaluated the influence of HUCPVCs 
CM on GBM aggressiveness and highlighted proteins 
from HUCPVCs CM potentially involved in the observed 
effects.
Our data shows that GBM cells exposed to HUCPVCs 
CM exhibit increased viability, migration and prolifera-
tion in  vitro (Figs.  1, 2, 3a, c). Interestingly, the in  vivo 
CAM model also showed an increase in tumor growth 
when GBM cells were exposed to HUCPVCs CM (Fig. 4). 
To the best of our knowledge, this is the first study on the 
influence of HUCPVCs CM in critical hallmark features 
of GBM.
Previous studies in different tumor types, including 
gliomas, are in agreement with our results, showing that 
MSCs may contribute to tumor growth/proliferation [3, 
4, 14, 39]. Additionally, it was also demonstrated that 
factors released by MSCs increased the migration abil-
ity of several types of cancer cells, including breast [71], 
colon [72], and gastric [73] cancers. Regarding gliomas, 
Onzi and colleagues demonstrated that ASCs CM treat-
ment was able to increase the migration capacity of U87 
GBM cells, which is in line with our results [74]. Inter-
estingly, despite the prominent effects of HUCPVCs CM 
Fig. 4 Effect of HUCPVCs conditioned media (CM) in GBM cells growth and angiogenesis, in vivo CAM model. Representative pictures of CAM assay 
after 8 days of tumor growth in ovo (a, b) and ex ovo (e, f) (× 16 magnification). c, d Tumor growth was measured in ovo. A higher tumor area was 
found in tumors originated from both U251 (c) and SNB-19 (d) cells exposed to HUCPVCs CM (p = 0.0260 for U251 and p = 0.0290 for SNB-19). g, h 
Number of blood vessels surrounding tumors derived from U251 (g) and SNB-19 (h) cells. Both U251 and SNB-19 tumors exposed to HUCPVCs CM 
presented an increase in the number of blood vessels comparing with control conditions, however only CM-exposed SNB-19 GBM tumors reached 
statistical significance (p = 0.1416 and p = 0.0069, respectively). Results are expressed as the mean ± SD (*p ≤ 0.05; **p ≤ 0.01). Dashed circle, 
tumor; Arrowheads, intra-tumoral blood vessel; Arrow, extra-tumoral blood vessel
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in multiple dimensions of GBM cell biology, the sensi-
tivity of these tumor cells to TMZ chemotherapy was 
not significantly affected by HUCPVCs CM (Fig. 3b, d). 
These results are in agreement with the work of Onzi 
and colleagues, where they demonstrated that ASCs 
CM treatment did not alter the response of U87 GBM 
cells to TMZ [74]. This absence of effect on the response 
of an anti-tumor drug (doxorubicin) was also recently 
observed in lung cancer cell lines when exposed to CM 
from Wharton’s jelly derived MSCs by Hendijani and 
co-workers [16]. Our study is the first to evaluate the 
influence of HUCPVCs CM on glioma growth and angio-
genesis in a CAM assay with formation of 3D microtu-
mors (Fig. 4). It was previously demonstrated that MSCs 
can induce angiogenesis in breast and colorectal cancer 
[75, 76], while in GBM these cells were associated with 
decreased angiogenesis [46]. In our work, we observed 
that exposure to HUCPVCs CM increased tumor blood 
vessels density, particularly in SNB-19 GBM tumors, 
suggesting that MSCs can induce angiogenesis, which 
may also contribute to higher tumor growth and tumor 
aggressiveness. Interestingly, GBM-associated stromal 
cells (GASCs), which are endogenously present in the 
tumor microenvironment, were previously shown to 
present properties of MSCs and have tumor-promoting 
effects on glioma [77–80], similarly to what we observed 
with HUCPVCs CM.
Taking into consideration that our study and others 
showed that MSCs can potentiate tumor aggressiveness, 
while others demonstrated that MSCs can be safely used 
as drug delivery agents [10, 39–41], it is crucial to stand-
ardize the methods used in different studies to more 
accurately understand if MSCs are definitely a valid and 
safe therapeutic approach to tackle cancer. Future studies 
should have into account several aspects, such as, tissue 
source and in vitro culture conditions of MSCs; type of 
Fig. 5 Functional analysis of proteins present in HUCPVCs conditioned media (CM). a–c DAVID was used to query the functional annotation of 
HUCPVCs secretome. The top 20 statistically significant enriched Gene Ontology (GO) terms in Biological Process (a), Molecular Component (b) and 
Molecular Function (c) are shown. d, e All statistically significant enriched Reactome (d) and KEGG (e) pathways are represented. The -log values of p 
values are displayed
Page 10 of 14Vieira de Castro et al. J Transl Med  (2017) 15:200 
tumor cells; variability of experimental methodology; and 
studies using modified MSCs should include unmodified 
MSCs as control. In addition, it will also be important 
to study low-passage primary GBM cell lines, instead of 
long-term established GBM lines, as these cells resemble 
more closely the original tumor characteristics, and are 
thus considered better models.
It is widely accepted that the major mechanism by which 
MSCs influence cancer pathophysiology is mediated by 
paracrine events [81–83]. In order to identify which factors 
secreted by HUCPVCs could be modulating the viability, 
proliferation, and migration of GBM cells, we performed 
proteomic analyses of HUCPVCs CM identifying 699 pro-
teins in the secretome. The functional clustering annotation 
and integration analyses (Fig.  5) revealed that HUCPVCs 
secretome had a significant enrichment in pathways that 
have been consistently found dysregulated in cancer (e.g. 
Wnt, PDGF and VEGF signaling pathways). In fact, these 
signaling pathways are known to mediate the pheno-
types we observed in GBM cells exposed to HUCPVCs 
CM (namely the increases in proliferation, migration, and 
invasion), further supporting our experimental findings 
[84–86]. For example, VEGF is one of the most important 
regulators of angiogenesis and subsequent tumor growth in 
GBMs [87–89]. In addition, the expression levels of VEGF 
in gliomas is correlated with poor prognosis and higher 
malignancy grades [90, 91]. Regarding PDGF, it was shown 
that this ligand and its receptors are involved in the prolif-
eration, differentiation and apoptosis of GBM cells, and are 
commonly overexpressed in GBMs [92, 93]. Finally, over-
activation of the Wnt signaling pathway has been associ-
ated with several tumor types, including GBM (reviewed 
in [94]), promoting tumor growth, migration and invasion 
[95–97]. Additionally, the expression levels of some genes 
of the Wnt pathway were found to be associated with poor 
prognosis in glioma patients [97, 98].
Similarly, particular proteins present in the secretome 
of HUCPVCs (Table 1), such as C-C motif chemokine 
2 (CCL2), platelet-derived growth factor C (PDGF-C), 
semaphorin-7A (Sema-7A), periostin, and interleukin 6 
(IL-6) are known to be important regulators of homeo-
stasis in a variety of physiological conditions, but have 
also been described to influence tumor cell behavior, as 
is the case of a classic proto-oncogene [99–121]. Inter-
estingly, IL-6, CCL2, and periostin were recently dem-
onstrated to promote M2 macrophage polarization, 
and thus contribute to tumor growth [122–124].
Conclusions
In conclusion, this work shows that HUCPVCs-secreted 
molecules contribute to GBM aggressiveness, by increas-
ing cell proliferation, migration and viability in  vitro, 
Table 1 Examples of proteins secreted by HUCPVCs that have been described to influence tumor cells’ behavior
Protein (coding gene) Findings in the context of cancer cells References
C-C motif chemokine 2 (CCL2) Regulates migration and invasion in several cancer types, including gliomas [99–101]
Actin-related protein 2/3 complex subunit 5 (ARPC5) Contributes to cell migration and invasion in head and neck squamous cell 
carcinoma
[102]
Translationally-controlled tumor protein (TPT1) Overexpressed in glioma tissue and is associated with tumor progression and 
poor clinical outcome of glioma patients. TCTP promotes glioma cell viability 
and proliferation, in vitro
[103, 104]
Platelet-derived growth factor C (PDGFC) Plays an important role in glioma vessel maturation and stabilization and in 
the progression of brain tumors, such as glioblastoma and medulloblastoma; 
and promotes tumor growth by recruitment of cancer-associated fibroblasts
[105–107]
Alpha-actinin-4 (ACTN4) Enhances the motility and invasion potential of various carcinoma cell lines [108]
Testican-1 (SPOCK1) Promotes the proliferation, migration and invasion and inhibits apoptosis in 
glioma cells
[109]
Neuropilin-2 (NRP2) Essential for breast cancer tumor initiation being involved in the formation of 
focal adhesions and is associated with metastasis and poor prognosis; and 
promotes the invasion and migration of thyroid cancer cells
[110–113]
Disintegrin and metalloproteinase domain-containing 
protein 10 (ADAM10)
Correlated with the grade of malignancy in human glioma; increases the 
migration capacity of glioma stem cells, and is implicated in U87 cell inva-
siveness
[114–116]
Transforming growth factor-beta-induced protein (TGFβI) Promotes cell adhesion of human astrocytoma cells, in vitro [117]
Plasminogen activator inhibitor 1 (SERPINE1) Essential in processes related to tumor development, like angiogenesis, adhe-
sion, migration, invasion and metastasis
[118]
Semaphorin-7A (SEMA7A) Contributes to the increases motility and decreases adhesion necessary for 
U87 cell invasion
[114]
Periostin (POSTN) Secreted periostin promotes glioma cell invasion and adhesion [119]
Interleukin 6 (IL6) Secreted IL6 promotes glioma cell invasion and angiogenesis [120, 121]
Page 11 of 14Vieira de Castro et al. J Transl Med  (2017) 15:200 
accompanied by higher tumor growth in  vivo. The pro-
teomic characterization identifies several putative mod-
ulators of these effects in GBM, warranting the need 
for further studies to understand their mechanisms of 
action on cancer cells. Our findings also contribute to 
the understanding of how tumor cells respond to MSCs-
released factors, raising concerns about the safety of their 
use as clinical tools for the treatment of GBM.
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